Tuesday, 12 January 2016

Allergic reactions occur due to a hypersensitivity disorder of the immune system against certain substances present in the environment, which are often referred as allergens such as dust mites excretion, pollen, and pet dander. Allergic reactions have a detrimental impact on the human health causing significant morbidity due to otolaryngologic, pulmonary, and dermatologic disorders. According to an article published by the National Center for Biotechnology Information (NCBI), over 500 million people are suffering from allergic rhinitis globally.

Browse Full Report With TOC:- http://www.transparencymarketresearch.com/allergy-diagnostics-market.html

The morbidity pattern varies from chronic illnesses such as allergic rhinitis and allergic asthma to acute anaphylaxis from venom or medication. Allergies are observed to affect all age groups, races and ethnicity and economic classes, although, young children and elderly are at higher risk. Factors such as alarming rise in pollution and environmental toxicity, overcrowding due to population rise, lifestyle factors are leading to weakened immune systems and heightened vulnerability towards allergic reactions.

According to the World Allergy Organization, nearly 30% to 40% of the global population is affected by one or the other allergic conditions and currently no cure is available for these disorders. Consequently, there is a burgeoning global market for diagnostic services to detect allergies caused by different allergens. The positive test alone demonstrates sensitization but do not always indicate clinical reactivity. The complexity of the allergy diagnosis lies in the fact that the diagnosis does not rest entirely on test results but also needs to incorporate patient’s medical history and the genetic predisposition towards certain allergies. Accurate diagnosis and immunotherapy is the only ray of hope for seeking cure against most of the allergen sensitivities.

Some of the allergy diagnostic products and services include allergy markers, ImmunoCAP, recombinant gene technology, and EliA blood tests among others. Allergy diagnostics market is bound to grow in future owing to the current health scenario with parallel rise in demand for accurate diagnostic tools and services. To enable diagnosis and disease management of allergies and autoimmune disorders, allergens have been classified on the basis of product type and end-users:

The end-users segment includes healthcare institutions such as medical research centers, laboratories, hospitals, and health insurance companies. Product types can be further subdivided into:
Assay Kits and immunoassay analyzers
Instruments
Consumables
Luminometers

Immunoassay analyzers are expected to capture a huge share among the global allergy diagnostics market and is poised to grow at the highest rate. To map out the diagnostic allergy market on a global scale, North America accounts for the largest regional market followed by Europe and opening up newer avenues for the rapidly growing markets in Asia-Pacific. This trend is further backed by the statistical information from the European Academy of Allergy and Clinical Immunology (EAACI) which reported in 2012 that nearly 17 million Europeans have food allergies and there has been seven-fold rise in allergic reactions among children over the past decade. One in every thirteen children (under 18 years of age) in the U.S is exposed to this potentially serious condition. Consequently, the market has witnessed a remarkably high growth owing to the increasing awareness coupled with government initiatives for the unmet needs of the population in many countries. It is anticipated that the sector will experience a tremendous growth as a result of the demand side factors, investments in the products and services for detecting the allergic trigger.

Some of the key players contributing to this market segment are Allercheck Laboratories, Inc., bioMérieux SA, Danaher Corporation, Hitachi Chemical Diagnostics, Inc., HOB Biotech Group Co., Ltd., HYCOR BioMedical, Lincoln Diagnostics, Inc., Omega Diagnostics Group plc, Siemens Healthcare, Stallergenes, and Thermo Fisher Scientific, Inc.

Request For Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=5147

About Us:-

Transparency Market Research (TMR) is a next-generation provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:-

Mr.Sudip.S
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
Spinal muscular atrophy is primarily a hereditary autosomal recessive disease that affects the nervous system areas that controls voluntary muscular movement. SMA is commonly identified as a genetic disorder causing mortality among people, especially infants. As per Orphanet, 1 infant out of 6,000 births is predicted to suffer spinal muscular atrophy. More than 10 mn individuals in the United States are carriers of spinal muscular atrophy. The spinal muscular atrophy market phase 3 candidate ISIS-SMNRx is predicted to reach US$0.47 bn by 2023.

Increasing Number of Infants with SMA to Drive Global Market

Recently, as per a news report, a few families in Morgantown found hope for their children who were suffering from spinal muscular atrophy. The families were denied access to the clinical trial drug SMNRx from ISIS Pharmaceuticals. Since then, the families, with the support of many others, have been trying to sign a petition to allow SMA-diagnosed children to have clear access to the relevant drugs for treatment.

Such and other events have occurred as the result of the growing prevalence of SMA among children. This will propel the global spinal muscular atrophy market in the coming years.

Browse Full Report: http://www.transparencymarketresearch.com/spinal-muscular-atrophy-market.html

Type 1 Spinal Muscular Atrophy to Lead Demand for Global SMA Market by 2023

Considering the increasing number of infants being diagnosed with spinal muscular atrophy, the spinal muscular atrophy market is expected to expand during the period from 2015 to 2023. On the basis of the symptoms and the age of onset, the SMA market is classified into Type 1 SMA, Type 2 SMA, Type 3 SMA, and Type 4 SMA. Type 1 spinal muscular atrophy is the most severe type and is found in infants aged up to six months. More than 60% of SMA cases are found to be Type 1 SMA, in which infants do not live for more than two years. Type 2 SMA affects children aged from six months to 18 months. Type 3 and 4 SMA are comparatively less severe and carry a prognosis of a normal lifespan. Physiotherapy is the best treatment suggested for SMA when it is at its early stage.

ISIS-SMNRx is an antisense medicine introduced by Isis Pharmaceutical and has shown positive results in clinical trials. Some other potential candidates are Olesoxime (TRO19622), RO6885247, scAAV9.CB.SMN, RG3039, LMI070, and CK-2127107. Phase 3 study of ISIS-SMNRx for treating Type 1 and Type 2 SMA is expected to be completed by 2016.

SMA is commonly diagnosed by recognizing mutation in the survival of motor neuron (SMN) gene. Muscle biopsy, nerve condition velocity, and electromyogram are some other ways by which SMA can be diagnosed. AveXis, Inc., F. Hoffmann-La Roche Ltd., Isis Pharmaceuticals, Inc., Cytokinetics, Inc., and Novartis AG are some of the prominent players in the spinal muscular atrophy market. 

Browse Press Release: http://www.transparencymarketresearch.com/pressrelease/spinal-muscular-atrophy-market.htm


At present, there is no well-defined cure for treating spinal muscular atrophy. ISIS-SMNRx is the only drug that is expected to be made available on large scale by 2017. The drug is expected to reach record sales of US$468.2 mn in the U.S. by 2023.

Monday, 19 October 2015

Spinal muscular atrophy (SMA) is a hereditary autosomal recessive disease affecting areas of the nervous system that control voluntary muscle movement. SMA is identified as a leading genetic disorder causing mortality among infants. According to Orphanet, one infant in 6,000 births is estimated to suffer from SMA. Furthermore, over 10 million people in the U.S. are carriers of SMA gene. Depending on the age of onset and symptoms, spinal muscular atrophy is classified in four main types. Type 1 SMA is the most severe form, and affects infants aged between zero and six months. Over 60% of annual SMA cases are of type 1 SMA, wherein infants usually do not survive for more than 2 years. Type 2 SMA is a moderate form affecting children aged between six months and eighteen months. Patients with Type 3 SMA and Type 4 SMA usually have a normal lifespan.
spinal-muscular-atrophy-market
Currently, no cure exists for spinal muscular atrophy, and treatment is directed towards managing common symptoms of SMA. Physiotherapy is strongly recommended in early stages of the disease to extend range of motion and improve muscle flexibility. Other treatment methods are targeted to treat gastrointestinal and respiratory disorders, which are common in SMA patients. The SMA pipeline is dry, with single drug in phase 3, three in phase 2, and one in phase 3 clinical trials. ISIS-SMNRx by Isis Pharmaceutical is an antisense drug that has shown promising results in phase 2 clinical trials. Phase 3 study of ISIS-SMNRx for treatment of Type 1 SMA and Type 2 SMA is expected to complete in 2016. In the United States, the drug is expected to reach annual sales of USD 0.47 billion by 2023. Olesoxime (TRO19622) has completed its phase2/3 trials, and has shown promising results, with potential to effectively treat type 2 and type 3 SMA. Other potential candidates include Olesoxime (TRO19622), LMI070, RO6885247, CK-2127107, scAAV9.CB.SMN and RG3039.

The United States and Europe have higher percentage of diagnosed cases of SMA. Government and private organization in these regions are also involved in creating awareness about the disease. Higher confirmed carrier population would also help in faster market growth in these regions. Furthermore, government incentives for development of therapeutic alternatives for rare diseases also boosts research and development in the SMA landscape.Companies with potential candidates in the spinal muscular atrophy pipeline include AveXis, Inc., Cytokinetics, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, and Isis Pharmaceuticals, Inc.   

Spinal Muscular Atrophy Pipeline is segmented as below:
Late Stage Candidates (Phase 3)
ISIS-SMN Rx

Early Stage Candidates (Phase 1 and Phase 2)

Olesoxime (TRO19622)
LMI070
RO6885247
CK-2127107
CB.SMN
RG3039

Request For Sample Report:- http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7187

Wednesday, 14 October 2015


Angina is a kind of chest pain or discomfort caused by poor flow of blood in the heart. This often occurs due to narrowing of blood arteries (atherosclerosis) caused by plaque formation or blood clot. People with obesity, history of heart disease, diabetes, high level of blood cholesterol and smoking are high risk of getting affected with angina. Some common symptoms associated with angina include pain, pressure or strange feeling in chest, shortness of breath, lightheadedness, irregular heartbeat, nausea or vomiting and weakness. Angina may be of two types: stable angina and unstable angina. Stable angina is the most common type of angina and is characterized by predictable pattern of chest pain. On the other hand, unstable angina has no typical pattern of chest pain. Stable angina happens when the heart does not get enough oxygen to perform a work which has been asked to do such as exercise or lifting heavy weight which may also occur due to cold weather and emotional stress.

Request For Brochure:- http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2214

Diagnosis of chronic stable angina includes medical history examination by a doctor and few tests such as coronary angiography, coronary risk profile (special blood tests), ECG, exercise tolerance test (stress test or treadmill test), stress echocardiogram and nuclear medicine (thallium) stress test. The treatment options for chronic stable angina include lifestyle changes such as daily exercise and quitting smoking, medications, and procedures such as angioplasty and stent placement and sometimes heart bypass surgery. Most commonly used medications include nitrates, ACE inhibitors and calcium channel blockers. Nicorandil, ranolazine and ivabradine are some of the latest anti-anginal agents which are also used for treating chronic stable angina.

The global market for chronic stable angina therapeutics is expected to grow at a moderate CAGR. Some major factors driving the market growth include high prevalence of the disease, extensive research and development of new more effective molecules. According to National Institute for Health and Clinical Excellence, an estimated 2 million people suffered from with stable angina in England in 2010. American Heart Association claims that around 9.1 million people are living with stable angina in the United States. Since stable angina cannot be cured immediately, it is expected that the base population of affected people will increase over the years and such high prevalence will drive market growth particularly in developed countries. The market for chronic stable angina therapeutics is likely to face significant challenges owing to patent expiry of major drugs such as bivalirudin (Angiomax/Angiox) in 2015 in Europe and rosuvastatin (Crestor) in 2016. These patent expiries are expected to attract generic manufacturers who will intensify the competition by selling drugs at low prices.

Geographically, North America represents the largest market, followed by Europe, Asia-Pacific and Rest of the World. In Asia-Pacific, rapid urbanization leading to life style changes and emerging economy of key countries such as India and China are expected to drive the market growth. Obesity, stress and cardiovascular diseases have become very common and will drive the market in developing countries significantly. Rapidly evolving medical tourism industry will also play a key role in driving the market growth in the region as a large number of people come from foreign countries to countries like India, Indonesia, Thailand and Singapore for the treatment of chronic stable angina.

There are many pharmaceutical companies and research institutes which are engaged in the development, manufacturing and marketing of drugs for treating chronic stable angina. Some major companies and research institutes include Pfizer, Inc., Mylan, Inc., Actavis Inc., Chong Kun Dang Pharmaceutical Corp., Roxane Laboratories, Inc., Gilead Sciences, Inc., CNS, Inc., Nanjing University and King's College London.

Browse Full Report With TOC:- http://www.transparencymarketresearch.com/chronic-stable-angina-therapeutics-market.html

This research report analyzes this market depending on its market segments, major geographies, and current market trends.
Geographies analyzed under this research report include
North America
Asia Pacific
Europe
Rest of the World 

This report provides comprehensive analysis of

Market growth drivers
Factors limiting market growth
Current market trends
Market structure
Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

About Us:-

Transparency Market Research (TMR) is a next-generation provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:-
Mr. Nachiket
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030

Wednesday, 26 August 2015

Nanocapsules are drug delivery agents within the size range of 10nm to 1000 nm that are normally composed of a capsule shell and a hollow space in which desired substance or drug molecules are embedded. The ultrafine size of nanocapsules match the biological composition of human body such as RBCs which permits enhanced permeation and retention (EPR) through narrow channels during diffusion. Due to this EPR effect, nanocapsules are used as drug carriers. Nanocapsules can be formulation using various methods such as loading of drug molecules into hollow polyelectrolyte shell and another method being electrostatic layer by layer (LbL) technique. These latest LbL self-assembled polyelectrolyte capsules provide an efficient way to perform multiple drug delivery tasks simultaneously. Some nanocapsules are used for targeted drug delivery in anti-tumor and anti-tuberculosis therapies wherein the outer sphere of nanocapsules is fabricated by the lithography technique. Lipid nanocapsules (DNA LNCs) and multimodular systems (DNA MMS) are used in gene therapy.

Browse Full Report With TOC:- http://www.transparencymarketresearch.com/nanocapsules-market.html


Global investment in nanotechnology research has witnessed a six fold increase during the last decade. Consequently, nanotechnology will completely revolutionize the industrial processes in the near future due to its remarkable economic potential. Some of the key drivers for the market growth include investments and breakthroughs in biomedical, pharmaceutical, electronics, molecular and diagnostic fields. Besides, these nanocapsules are being increasingly used in agrochemicals, environment and wastewater treatments, genetic engineering, consumer goods and cosmetic procedures. Some of the most advanced future applications would be nanocapsule dressings to deliver antibiotics aiding faster wound healing without invasion to the skin. These nanocapsule bandages would be consistently demanded by defence and protection forces as they need not be changed periodically. According to the experts, electronics and magnetic sector will be the largest potential market for nanocapsules, followed by biopharmaceutical industry, catalysis, energy and engineering. However, growth in the nanocapsules market will also pose new challenges with respect to the toxicity and environmental impact of nanocapsules. Recently efforts have been made to overcome these drawbacks by developing eco-friendly versatile nanocapsules. For instance, nanocapsules introduced by the Center for Self-assembly and Complexity, Institute for Basic Science (IBS). Other factors such as cost escalation and consequences on the global economy especially in cases of under-developed economies with poor R&D investment would exhibit low social and ethical acceptance of nanocapsules.

Funding for nanotechnology is soaring worldwide at a competitive level, with each major economic power and many developed economies making a substantial investment to revamp their industrial and postindustrial supply chains. Technological inventions and discoveries in nanotechnology would cause tremendous growth in the global nanocapsule market. Due to a variety of potential applications, nanotechnology is expected to become the key technology in the near future. U.S. has invested around USD 3.7 billion through its National Nanotechnology Initiative for research activities. The European Union had spent approximately USD 1.2 billion and Japan USD 750 million by 2012. Moreover, there is a steady demand for medically advanced procedures in developed as well as developing regions having a well-established healthcare infrastructure. In the Asia Pacific region, the demand for nanocapsules is projected to rise owing to the high disease burden of tuberculosis and cancer. Some of the key factors that are likely to contribute toward the market growth are growing awareness about genetic counselling, genetic disorders, high prevalence of tuberculosis and multi-drug resistant tuberculosis, increasing trend in cancer and tumor ailments and surging demand for oncological treatments.

Presently, nanocapsules are under different stages of clinical trial phases facing several hurdles to gain market entry. However, few commercially available nanocapsules which are now commercially used as several pigments in sunscreen, scratch resistance coatings, catalysts, and biomarkers. Some of the key market players for these commercially available nanocapsules are Abraxis, Artificial Cell Technologies, Inc., BioDelivery Sciences International, Inc., Biophan Technologies, Inc., Cornerstone Pharmaceuticals, Inc., Genetic Immunity, Inc., Keystone Nano, Inc., Makefield Therapeutics, Inc., Nanospectra Biosciences, Inc., and Mersana Therapeutics, Inc.

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. This report provides comprehensive analysis of
Market growth drivers
Factors limiting market growth
Current market trends
Market structure
Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Reasons for Buying this Report:-

  • This report provides pin-point analysis for changing competitive dynamics
  • It provides a forward looking perspective on different factors driving or restraining market growth
  • It provides a six-year forecast assessed on the basis of how the market is predicted to grow
  • It helps in understanding the key product segments and their future
  • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
  • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
  • It provides distinctive graphics and exemplified SWOT analysis of major market segments

Get Sample Report:- http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=5321

About Us:-
Transparency Market Research (TMR) is a next-generation provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:-

Mr.Nachiket
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

Monday, 24 August 2015


Ischemia is characterized by a specific condition, where there is an insufficient flow of blood supply to tissues, leading to a shortage of oxygen and glucose which is needed for cellular metabolism. Due to an obstruction and insufficient blood supply, various organs and tissue get severely damaged. Ischemia, if left untreated, may lead to tissue death. Ischemia is primarily caused by thrombosis of an artery, embolism, vasculitis, atherosclerosis, coronary artery disease and peripheral artery disease. There are various types of ischemia with different diagnosis and treatment methods involved with each type of ischemia. 


Based on the types, ischemia market can be segmented as follows:
  • Myocardial ischemia: Due to blockage of a coronary artery, there is a limited blood flow to the heart muscle and is referred to as myocardial ischemia. Symptoms include arm pain, chest pain, breathlessness, dizziness, weakness, heart palpitations and clammy skin.
  • Cerebral ischemia: Cerebral ischemia occurs when there is a temporary deficiency of blood supply to an individual’s brain. Symptoms include difficulty in speaking, lack of coordination, body movement problems, vision impairment and unconsciousness.
  • Intestinal ischemia: Ischemia affects intestine too, and this condition is known as intestinal ischemia. Various symptoms include abdominal pain, fever, diarrhea, vomiting, bloody stools and weight loss.
  • Hepatic ischemia: In hepatic ischemia, an individual’s liver does not receive enough blood supply. Hypotension is the prime cause of hepatic ischemia and symptoms include dehydration, heart failure, severe bleeding and abnormal heart rhythms. 
  • Acute limb ischemia: Decreased level of blood flow to hands, feet and legs leads to acute limb ischemia. Symptoms include skin ulcers, skin sores and severe pain.
Based on treatment, the ischemia can be segmented as follows:
  • Medications:
    • Angiotensin-converting enzyme (ACE) inhibitors
    • Anticoagulants
    • Aspirin
    • Analgesics
    • Beta blockers
    • Nitroglycerine
  • Surgery methods:
    • Angioplasty, also referred to as percutaneous coronary intervention (PCI)
    • Coronary artery bypass surgery
    • Embolectomy
    • Aortomesenteric bypass and resection of bowel
Based on geography, the ischemia market can be segmented into four major regions: North America, Europe, Asia Pacific and Rest of the World (RoW). Out of these regions, North America dominates the ischemia market followed by Europe. The prime factors which would drive the growth of the market in these regions are growing prevalence of high cholesterol diseases, increasing incidences of obesity and physical inactivity. Moreover, technological advancements and increasing competition from small market players have further fueled the growth of ischemia market. According to a survey, approximately 1.5 million cases of myocardial ischemia occur annually in the United States. Moreover, technological advancements and increasing competition from small market players have further fueled the growth of ischemia market. Asia Pacific is one of the most promising markets for the growth of ischemia market due to easy market penetration. 

The factors which would augment the growth of the market in Asia Pacific are increasing geriatric population, high prevalence of unhealthy lifestyle amongst the population and increasing awareness regarding the malignant effects of ischemia. Other factors such as tax benefits and increasing disposable incomes of the population would further propel the growth of ischemia market.


Various biopharmaceutical companies are constantly coming up with novel therapeutics for the treatment of ischemia. Some of the top players operating in the ischemia market are Sanofi, Pfizer, Inc., Medicure, Inc., Baxter International, Boston Scientific Corporation, Vasade Biosciences, Inc. and others.

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
North America
Asia Pacific
Europe
Rest of the World

This report provides comprehensive analysis of
Market growth drivers
Factors limiting market growth
Current market trends
Market structure
Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Reasons for Buying this Report
This report provides pin-point analysis for changing competitive dynamics
It provides a forward looking perspective on different factors driving or restraining market growth
It provides a six-year forecast assessed on the basis of how the market is predicted to grow
It helps in understanding the key product segments and their future
It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
    

About Us:-
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us:-
Mr. Nachiket Ghumare
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

Tuesday, 17 June 2014

According to a new market report published by Transparency Market Research  "Neuromodulation Devices Market - Global Industry Analysis, Size, Share and Forecast, 2012 - 2018 " the global neuromodulation devices market was valued at USD 2,758 million in 2011 and is expected to grow at a CAGR of 14.4% from 2012 to 2018, to reach an estimated value of USD 7,072.6 million by 2018.

Browse the  Neuromodulation Devices Market report with full TOC at http://www.transparencymarketresearch.com/global-neuromodulation-devices-market.html

The market is driven by factors such as the aging world population leading to chronic diseases such as Parkinson´s and Alzheimer´s disorders and technological advancements in the field of neuromodulation devices including the invention of transversal neuromodulation technology by NMT (Neurowave Medical Technologies). Moreover, the rising prevalence of chronic diseases, increasing demand for minimally invasive surgeries, the availability of external funding to conduct clinical studies to help come up with new and technologically advanced products and the rising healthcare related consumer expenditure have also driven the growth in this market. The fact that a neuromodulation device could be used as an add-on treatment and so can be used simultaneously with other medications also drives the market forward.


The North American region holds majority of the market share and accounted for a share of 65% in 2011. The North American neuromodulation device market was valued at USD 1,792.7 million in 2011. The economic developments in the Asia Pacific region make it the fastest growing region (CAGR of more than 15% from 2012 to 2018) in the neuromodulation devices market.

Browse all Pharmaceutical Market Research Reports @http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

The future growth of the market will be ensured by capitalizing on market opportunities such as increasing healthcare related consumer expenditure in emerging economies in the Asia Pacific, Latin American and Eastern European regions. The availability of medical device manufacturing outsourcing options helps in curbing costs and thereby enhances profit margins. Also, the presence of consolidation options in the healthcare industry helps in strengthening the revenue base to conduct R&D exercises for new product development and thus helps in strengthening market share.